An Open-label, Phase 1, First-in-human, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Maximum Tolerated or Administered Dose, Pharmacokinetics, Pharmacodynamics and Tumor Response Profile of the Aryl Hydrocarbon Receptor Inhibitor (AhRi) BAY 2416964 in Participants With Advanced Solid Tumors
In this study researchers want to gather relevant information regarding the safety of
BAY2416964 and how well the drug works in participants with a type of solid tumors that
cannot be cured by currently available drugs. Researchers want to find the highest dose of
BAY2416964 that participants could take without having too many side effects, how the drug is
tolerated and the way the body absorbs, distributes and gets rid of the study dug. BAY2416964
is a small molecule which blocks the Aryl Hydrocarbon Receptor (a protein involved in immune
cell reaction to tumor cells) allowing the body to use its immune response against the tumor
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.